Utpal Koppikar

Filings by Utpal Koppikar span 2 companies, the busiest being Atara Biotherapeutics, Inc. and C4 Therapeutics, Inc. Between 18 May 2021 and 2 March 2023, the trades on record add up to 13 filings.

Both buying and selling appear: 1 purchase worth €30k, against 11 sales worth €377k. Sales outweigh purchases by €347k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant. So far in 2023, the count stands at 1 purchase and 2 sales.

Most recently, on 6 March 2023, the filings show an open-market sale worth €23k in Atara Biotherapeutics, Inc. The clock since the last published purchase (10 February 2023) now reads 1,346 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.